help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, P.
Right arrow Articles by Scicli, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, P.
Right arrow Articles by Scicli, A. G.
(American Journal of Pathology. 2005;166:615-624.)
© 2005 American Society for Investigative Pathology

Inhibitors of Cytochrome P450 4A Suppress Angiogenic Responses

Ping Chen*, Meng Guo*, Dana Wygle*, Paul A. Edwards*, John R. Falck{dagger}, Richard J. Roman{ddagger} and A. Guillermo Scicli*§

From the Eye Care Services,* Henry Ford Health System, and Anesthesiology, § Wayne State University, Detroit, Michigan; the Departments of Biochemistry and Pharmacology,{dagger} University of Texas Southwestern Medical Center, Dallas, Texas; and the Department of Physiology,{ddagger} Medical College of Wisconsin, Milwaukee, Wisconsin

Cytochrome P450 enzymes of the 4A family (CYP4A) convert arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE) in blood vessels of several vascular beds. The present study examined the effects of inhibiting the formation of 20-HETE with N-hydroxy-N'-(4-butyl-2-methylphenol) formamidine (HET0016) on the mitogenic response of vascular endothelial growth factor (VEGF) in human umbilical vein endothelial cells (HUVECs) in vitro, and on growth factor-induced angiogenesis in the cornea of rats in vivo. HET0016 (10 µmol/L and 20 µg, respectively) abolished the mitogenic response to VEGF in HUVECs and the angiogenic response to VEGF, basic fibroblast growth factor, and epidermal growth factor in vivo by 80 to 90% (P < 0.001). Dibromododecenyl methylsulfonimide (DDMS), a structurally and mechanistically different inhibitor of 20-HETE synthesis, also abolished angiogenic responses when tested with VEGF. Additionally, administration of the stable 20-HETE agonist, 20-hydroxyeicosa-6(Z) 15(Z)-dienoic acid (WIT003) induced mitogenesis in HUVECs and angiogenesis in the rat cornea in vivo. We studied the ability of HET0016 to alter the angiogenic response in the rat cornea to human glioblastoma cancer cells (U251). When administered locally into the cornea, HET0016 (20 µg) reduced the angiogenic response to U251 cancer cells by 70%. These results suggest that a product of CYP4A product, possibly 20-HETE, plays a critical role in the regulation of angiogenesis and may provide a useful target for reduction of pathological angiogenesis.




This article has been cited by other articles:


Home page
 Am. J. Physiol. Renal Physiol.Home page
F. Park, W. E. Sweeney Jr., G. Jia, T. Akbulut, B. Mueller, J. R. Falck, S. Birudaraju, R. J. Roman, and E. D. Avner
Chronic blockade of 20-HETE synthesis reduces polycystic kidney disease in an orthologous rat model of ARPKD
Am J Physiol Renal Physiol, March 1, 2009; 296(3): F575 - F582.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Tang, E. A. Scheef, S. Wang, C. M. Sorenson, C. B. Marcus, C. R. Jefcoate, and N. Sheibani
CYP1B1 expression promotes the proangiogenic phenotype of endothelium through decreased intracellular oxidative stress and thrombospondin-2 expression
Blood, January 15, 2009; 113(3): 744 - 754.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. M. Guo, J. Sheng, G. M. Scicli, A. S. Arbab, N. L. Lehman, P. A. Edwards, J. R. Falck, R. J. Roman, and A. G. Scicli
Expression of CYP4A1 in U251 Human Glioma Cell Induces Hyperproliferative Phenotype in Vitro and Rapidly Growing Tumors in Vivo
J. Pharmacol. Exp. Ther., October 1, 2008; 327(1): 10 - 19.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. Park, W. E. Sweeney, G. Jia, R. J. Roman, and E. D. Avner
20-HETE Mediates Proliferation of Renal Epithelial Cells in Polycystic Kidney Disease
J. Am. Soc. Nephrol., October 1, 2008; 19(10): 1929 - 1939.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
M. Medhora, Y. Chen, S. Gruenloh, D. Harland, S. Bodiga, J. Zielonka, D. Gebremedhin, Y. Gao, J. R. Falck, S. Anjaiah, et al.
20-HETE increases superoxide production and activates NAPDH oxidase in pulmonary artery endothelial cells
Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L902 - L911.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
U. R. Michaelis, N. Xia, E. Barbosa-Sicard, J. R. Falck, and I. Fleming
Role of Cytochrome P450 2C Epoxygenases in Hypoxia-Induced Cell Migration and Angiogenesis in Retinal Endothelial Cells
Invest. Ophthalmol. Vis. Sci., March 1, 2008; 49(3): 1242 - 1247.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
T. Ishizuka, J. Cheng, H. Singh, M. D. Vitto, V. L. Manthati, J. R. Falck, and M. Laniado-Schwartzman
20-Hydroxyeicosatetraenoic Acid Stimulates Nuclear Factor-{kappa}B Activation and the Production of Inflammatory Cytokines in Human Endothelial Cells
J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 103 - 110.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. M. Guo, A. S. Arbab, J. R. Falck, P. Chen, P. A. Edwards, R. J. Roman, and A. G. Scicli
Activation of Vascular Endothelial Growth Factor through Reactive Oxygen Species Mediates 20-Hydroxyeicosatetraenoic Acid-Induced Endothelial Cell Proliferation
J. Pharmacol. Exp. Ther., April 1, 2007; 321(1): 18 - 27.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. Diani-Moore, F. Papachristou, E. Labitzke, and A. B. Rifkind
INDUCTION OF CYP1A AND CYP2-MEDIATED ARACHIDONIC ACID EPOXYGENATION AND SUPPRESSION OF 20-HYDROXYEICOSATETRAENOIC ACID BY IMIDAZOLE DERIVATIVES INCLUDING THE AROMATASE INHIBITOR VOROZOLE
Drug Metab. Dispos., August 1, 2006; 34(8): 1376 - 1385.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Guo, R. J. Roman, J. D. Fenstermacher, S. L. Brown, J. R. Falck, A. S. Arbab, P. A. Edwards, and A. G. Scicli
9L Gliosarcoma Cell Proliferation and Tumor Growth in Rats Are Suppressed by N-Hydroxy-N'-(4-butyl-2-methylphenol) Formamidine (HET0016), a Selective Inhibitor of CYP4A
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 97 - 108.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
M. Guo, R. J. Roman, J. R. Falck, P. A. Edwards, and A. G. Scicli
Human U251 Glioma Cell Proliferation Is Suppressed by HET0016 [N-Hydroxy-N'-(4-butyl-2-methylphenyl)formamidine], a Selective Inhibitor of CYP4A
J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 526 - 533.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Pozzi, I. Macias-Perez, T. Abair, S. Wei, Y. Su, R. Zent, J. R. Falck, and J. H. Capdevila
Characterization of 5,6- and 8,9-Epoxyeicosatrienoic Acids (5,6- and 8,9-EET) as Potent in Vivo Angiogenic Lipids
J. Biol. Chem., July 22, 2005; 280(29): 27138 - 27146.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. V. Ljubimov and M. B. Grant
P450 in the Angiogenesis Affair: The Unusual Suspect
Am. J. Pathol., February 1, 2005; 166(2): 341 - 344.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology.